ArticleVascular specialist international2026
Mid-term Outcomes Following Primary Covered Stent Implantation in Supra-Aortic Arch Vessels for Atherosclerotic Occlusive Disease.
Article in Vascular specialist international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to present the mid-term outcomes of patients undergoing treatment for atherosclerotic stenosis or occlusion of the supra-aortic arch vessels using covered stents. Materials and Methods: We conducted a retrospective, single-center analysis of patients treated for supra-aortic arch vessel atherosclerotic occlusive disease (AOD) at our institution between 2015 and 2024. The study included symptomatic patients who received endovascular treatment with covered stents for lesions involving the subclavian artery, proximal common carotid artery (pCCA), or the brachiocephalic trunk (BT). All patients underwent preprocedural computed tomography angiography within 6 months and color duplex ultrasonography before and after the intervention. Results: A total of 20 patients (8 male; mean age, 69.5±14.3 years) underwent primary covered stent implantation for supra-aortic arch vessel AOD, with 21 vessels treated (11 [52.4%], 6 [28.6%], and 4 [19.0%] in the subclavian artery, pCCA, and BT respectively). The main presenting symptoms were related to cerebrovascular insufficiency. Two patients presented with ischemic finger lesions due to subclavian artery occlusion. Technical success rate was 100% (21/21), and no intraoperative complications were recorded. Perioperative mortality was 0%. Two patients developed transient cerebral hyperperfusion syndrome after pCCA recanalization, one required temporary hemodialysis, and one underwent wound revision for access-site hematoma. Sixteen patients reported postoperative symptom resolution. Mean follow-up was 47.9±33.1 months (median, 40 months; interquartile range, 32 months). Mortality during follow-up was 30% (6/20), with no AOD-related deaths. During follow-up, no duplex ultrasound findings suggestive of >50% in-stent restenosis were detected, and no reinterventions were required. Conclusion: Covered stent implantation for supra-aortic arch vessel atherosclerotic lesions appears to be associated with acceptable mid-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.